<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99201">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988558</url>
  </required_header>
  <id_info>
    <org_study_id>LA-001-IL</org_study_id>
    <nct_id>NCT01988558</nct_id>
  </id_info>
  <brief_title>A Phase I/II to Assess Safety, Tolerability and Efficacy of DL-lactic Acid Syrup in Children With Recurrent Tonsillitis</brief_title>
  <official_title>A Phase I/II, Randomized, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of DL-lactic Acid Syrup (Tonsitin) in Children With Recurrent Tonsillitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yali Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yali Pharmaceuticals</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objectives are to evaluate Tonsitinâ„¢ (10% Lactic Acid) safety, tolerability and
      preliminary efficacy, as a potent treatment for Recurrent Tonsillitis in children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety evaluation - Number of participants with adverse events</measure>
    <time_frame>At 90 days post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tonsil Size</measure>
    <time_frame>Chnge from baseline at 6 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tonsillitis episodes</measure>
    <time_frame>Chnge in medical history number of recurrent Tonsillitis episodes within 6 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>QOL Questionnaire</measure>
    <time_frame>Chnge from baseline at 90 days post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Recurrent Tonsillitis in Children</condition>
  <arm_group>
    <arm_group_label>Treated Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DL - Lactic Acid</intervention_name>
    <description>Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)</description>
    <arm_group_label>Treated Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Raspberry flavored syrup</intervention_name>
    <description>Placebo group to receive Raspberry flavored Syrup</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children at the ages of 5-16.

          -  Patient is suffering from recurrent documented sore throat with at least 4
             tonsillitis episodes during the preceding year (at least one verified by culture or
             rapid antigen testing for Streptococcus A).

          -  Patient with clinical presentation of irregular tonsils.

          -  Tonsils size graded between 2.5-4.

          -  Clinical diagnosis of bacterial known in recurrent pharyngeal-tonsillitis.

          -  Patient is willing to participate in the study and adhere to the study protocol

          -  Patient's guardian and/or Patient have signed informed consent.

        Exclusion Criteria:

          -  Clinical diagnosis of acute tonsillitis/pharyngitis caused by Streptococcus pyogenes
             (Positive RSAT or microbial culture).

          -  Subjects who are known as Streptococcus pyogenes carriers

          -  Subject's requiring any other medication (topical or systemic) that may affect the
             course of the disease during the study period (e.g. antibiotics, sedating
             antihistamines), and/or did not completed 14 days from end of antibiotics treatment.

          -  Subjects with known hypersensitivity to lactose.

          -  Subject is suffering from peritonsillar abscess.

          -  Subject suffers from an active peptic ulcer

          -  Subjects who are suffering from any concomitant disease which in the judgment of the
             investigator will interfere with the conduct or interpretation of the study results.

          -  Subject is currently participating in another clinical study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mati Berkovitz, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MOH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe T Neuman, PhD</last_name>
    <phone>972-8-9366700</phone>
    <phone_ext>0</phone_ext>
    <email>moshe@brd.co.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Tzrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mati Berkovitz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>November 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Tonsillitis</keyword>
  <keyword>Streptococcus A</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
